Scientific Presentations Highlight OGM’s Utility for Cancer Research at Joint Annual Meeting for Three Molecular and Cytogenetic Associations

• At a sponsored workshop, Su Yang from The University of Texas MD Anderson Cancer Center will present case studies that demonstrate the ability of the optical genome mapping (OGM) workflow to detect pathogenic structural and copy number variants relevant to hematological cancer research
• Dr. Ying Zhou from The Johns Hopkins University School of Medicine and Dr. Wahab Khan from Dartmouth Hitchcock Medical Center will each lead educational sessions on the utility of OGM across cancer cytogenetic research applications

SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) — Bionano Laboratories, a clinical laboratory services business of Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical genome mapping (OGM) will be featured in three scientific presentations at the 2024 joint annual meeting for the American Society for Clinical Laboratory Science (ASCLS), the Association of Genetic Technologists (AGT), and the Society of American Federal Medical Laboratory Scientists (SAFMLS). The conference, which brings together laboratory professionals and industry partners affiliated with three professional societies for networking and educational sessions focused on chemistry, microbiology, hematology, molecular diagnostics and cytogenetics, will be held July 8-12, 2024, in Pittsburgh, Pennsylvania and online.

At a sponsored scientific workshop titled “Revolutionizing hematological disease: unraveling genomic mysteries with optical genome mapping,” Su Yang, CG (ASCP), from The University of Texas MD Anderson Cancer Center, will present cancer research case studies that demonstrate OGM’s ability to detect structural abnormalities in hematological samples at high sensitivity and resolution.

A session titled “Clinical utilities of optical genome mapping at clinical cytogenetic labs,” led by Ying Zhou, MD, PhD, FACMG, of The Johns Hopkins University School of Medicine, will cover the ability of the OGM workflow to detect structural and copy number variants relevant to cancer research.

Wahab Khan, PhD, FACMG, from Dartmouth Hitchcock Medical Center, will present at a session titled “Setting up optical genome mapping in your cytogenetic laboratory: points for consideration in analysis and test validation,” where he will cover the implementation and validation of OGM for cancer cytogenetic research applications.

“We are pleased to see a number of sessions at this joint conference from leading medical centers that highlight OGM as a cutting-edge tool for molecular and cytogenetic research, due to its high sensitivity and resolution and simple workflow. We believe laboratory professionals across the globe will continue to adopt and utilize the OGM workflow due to its potential to positively impact cancer and other research applications,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano.

More details on the conference can be found here.

About Bionano Laboratories:

Bionano Laboratories provides access to genetic answers and support utilizing cutting-edge technologies to advance the way the world sees the genome.  Its clinical diagnostics services offer optical genome mapping (OGM) testing that combines a comprehensive testing portfolio with thoughtful and accessible support options. Bionano Laboratories also offers direct access to OGM for applications across basic, translational and clinical research. For more information, visit www.bionanolaboratories.com

About Bionano

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.

For more information, visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.

Forward-Looking Statements of Bionano Genomics

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “ability,” “believe,” “potential,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, OGM’s ability to detect pathogenic structural and copy number variants relevant to hematological cancer research; OGM’s ability to detect structural abnormalities in hematological samples at high sensitivity and resolution; OGM’s utility across cancer cytogenetic research applications; the utility of OGM for research in the areas reported in the presentations given and the posters made available at the 2024 joint annual meeting for ASCLS, AGT, and SAFMLS, and the growth and adoption of OGM for use in hematologic research applications. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: global and macroeconomic events, such as recent and potential bank failures, supply chain disruptions, global pandemics, inflation, and the ongoing conflicts between Ukraine and Russian and Israel and Hamas, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; failure of OGM’s ability to detect pathogenic structural and copy number variants relevant to hematological cancer research; failure of OGM’s ability to detect structural abnormalities in hematological samples at high sensitivity and resolution; failure of OGM’s utility across cancer cytogenetic research applications; failure of researchers to adopt OGM; failure of our OGM solutions to offer the anticipated benefits for and contributions to the areas reported in the presentations given and posters made available at the 2024 joint annual meeting for ASCLS, AGT, and SAFMLS; future study results contradicting the results reported in the presentations given and posters made available at the 2024 joint annual meeting for ASCLS, AGT, and SAFMLS; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; our ability to effectively manage our uses of cash, and our ability to continue as a “going concern”; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2023 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACTS

Company Contact:

Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com

Investor Relations:

David Holmes
Gilmartin Group
+1 (858) 888-7625
IR@bionano.com